Based in Lyon, France, Poxel was spun off in 2009 from Merck Serono, a leading global player in the field of metabolic disorders. Poxel operates independently as a lean organization, led by a highly experienced management team with strong expertise in all aspects of drug development and an extensive scientific and pharmaceutical industry network.
Poxel's lead compound, Imeglimin, is in Phase II clinical development for Type 2 diabetes and has shown excellent efficacy and safety to date. The company's pipeline contains several other compounds with innovative, disease-modifying mechanisms of action that are being developed as safer, more effective alternatives to existing therapies. Poxel raised €16 million in a Series A financing in July 2010. The company intends to develop its compounds internally to the end of Phase II and seek partnerships for further clinical development and commercialization.